US11998583B2 - Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof - Google Patents

Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof Download PDF

Info

Publication number
US11998583B2
US11998583B2 US17/788,010 US202017788010A US11998583B2 US 11998583 B2 US11998583 B2 US 11998583B2 US 202017788010 A US202017788010 A US 202017788010A US 11998583 B2 US11998583 B2 US 11998583B2
Authority
US
United States
Prior art keywords
parts
radix
fructus forsythiae
aqueous extract
radix astragali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/788,010
Other versions
US20230040479A1 (en
Inventor
Xiaosong Gu
Chunkang TANG
Leilei Gong
Yu Zhang
Qiong Cheng
Xiaoming Yang
Xiaomin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong University
Original Assignee
Nantong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantong University filed Critical Nantong University
Publication of US20230040479A1 publication Critical patent/US20230040479A1/en
Assigned to NANTONG UNIVERSITY reassignment NANTONG UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHENG, QIONG, GONG, Leilei, GU, XIAOSONG, TANG, Chunkang, WANG, XIAOMIN, YANG, XIAOMING, ZHANG, YU
Application granted granted Critical
Publication of US11998583B2 publication Critical patent/US11998583B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present disclosure relates to a Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof, and relates to the technical field of medicines.
  • Influenza (called the flu for short) is a respiratory tract infection mainly caused by influenza viruses, and is high in infectivity and spread rate.
  • the typical clinical symptoms are fever, headache, limb soreness, sneezing, dry throat, sore throat, cough and weakness.
  • the present disclosure provides a Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof.
  • a Fructus Forsythiae and Radix Astragali compound preparation including traditional Chinese medicine formulation components.
  • the traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae.
  • the traditional Chinese medicine formulation components consist of the following components in parts by mass: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisiae Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae.
  • the Fructus Forsythiae and Radix Astragali compound preparation includes an effective dose of the traditional Chinese medicine formulation components and a pharmaceutically acceptable excipient.
  • dosage forms of the Fructus Forsythiae and Radix Astragali compound preparation include an oral liquid, a granule, a dissolved medicine, and a tablet.
  • a preparation method for a Fructus Forsythiae and Radix Astragali oral liquid including
  • a preparation method for a Fructus Forsythiae and Radix Astragali granule including:
  • a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease is provided.
  • monarch herbs include: Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, and Herba Artemisiae Annuae; minister herbs include: Radix Astragali, stir-fried Rhizoma Atractylodis Macrocephalae, and Herba Pogostemonis; assistant herbs include: Radix Saposhnikoviae and Radix Ophiopogonis; and an envoy herb is Radix Glycyrrhizae.
  • the formulation has functions of clearing heat and removing toxic substances, inhibiting virus activity, nourishing yin and relieving cough, benefiting lung and tonifying spleen, strengthening body resistance and eliminating pestilence.
  • the formulation is applicable to influenza, fever, headache, limb soreness, sore throat, cough and asthenia.
  • beneficial effects of the Fructus Forsythiae and Radix Astragali compound preparation, and the preparation method therefor and the use therefor provided in the present invention are: firstly, pharmaceutical components of the formulation are different from those of the existing related traditional Chinese medicines, and the pharmaceutical composition of the formulation is unique and novel.
  • an innovative point of efficacy of the drugs of the formulation lies in that by means of the pharmaceutical composition of the formulation, a strong medicine combined antiviral effect may be generated, and the immune function of the human body is further improved, so as to achieve a desirable integrated synergistic antiviral effect.
  • Flos Lonicerae, Fructus Forsythiae, and Radix Scutellariae all have antiviral effects, and the three traditional Chinese medicines are used in combination in the formulation to enhance the medicine antiviral effect.
  • Radix Scutellariae and Radix Glycyrrhizae in the formulation play a better integrated and synergistic antiviral effect by regulating the immune function of the human body, effectively inhibit virus activity, relieve symptoms of a patient, and achieve efficacy of strengthening body resistance and eliminating pathogens.
  • a dialectical theory of the formulation on influenza treatment is unique and innovative, the innovative point is to propose “nourishing yin and relieving cough, benefiting lung and tonifying spleen, strengthening body resistance and eliminating pestilence” based on traditional heat clearing and toxic substance removing.
  • Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, and Herba Artemisiae Annuae enter lungs, a stomach, a liver, a gallbladder and a large intestine meridian, and have effects of clearing heat and removing toxic substances, clearing lung heat and relieving cough;
  • Radix Astragali, stir-fried Rhizoma Atractylodis Macrocephalae and Herba Pogostemonis have effects of benefiting qi and reinforcing spleen, and enhance resistance of the human body;
  • compatibility of Radix Saposhnikoviae with Radix Astragali and Rhizoma Atractylodis Macrocephalae is Yupingfeng San, and achieves functions of tonifying qi, consolidating superficial resistance, enhancing the immune function of the human body, and strengthening the body resistance.
  • Herba Artemisiae Annuae reduces fever, Herba Pogostemonis eliminates dampness with aromatics, and clears lung-heat and relieves coughing.
  • Radix Ophiopogonis nourishes yin and promotes production of body fluid, nourishes the lung to arrest coughing.
  • Radix Glycyrrhizae invigorates spleen and replenishes qi, clears heat and removes toxic substances, and regulates various drugs to exert a synergistic effect.
  • Raw materials of a formulation are as follows: 100 parts of Flos Lonicerae, 100 parts of Fructus Forsythiae, 100 parts of Radix Scutellariae, 100 parts of Herba Artemisiae Annuae, 100 parts of Radix Astragali, 100 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 100 parts of Herba Pogostemonis, 60 parts of Radix Saposhnikoviae, 100 parts of Radix Ophiopogonis, and 60 parts of Radix Glycyrrhizae.
  • Raw materials of a formulation are as follows: 100 parts of Flos Lonicerae, 100 parts of Fructus Forsythiae, 100 parts of Radix Scutellariae, 100 parts of Herba Artemisiae Annuae, 100 parts of Radix Astragali, 100 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 100 parts of Herba Pogostemonis, 60 parts of Radix Saposhnikoviae, 100 parts of Radix Ophiopogonis, and 60 parts of Radix Glycyrrhizae.
  • a stock solution (15.6 g crude drug/kg) prepared from Fructus Forsythiae and Radix Astragali granules; ribavirin (positive control, 0.075 g/kg); and chicken embryo, influenza a virus FM1 strain, and ICR mice.
  • mice are randomly divided into four groups, each group has six mice, and a normal group, a model group, a ribavirin group, and a Fructus Forsythiae and Radix Astragali granule group are set.
  • the mice are intragastrically administered twice a day, 0.3 ml each time, and the mice in the normal group are administered with double-distilled water at the same dose for five consecutive days.
  • the mice are infected intranasally with virus allantoic droplets, at 15 LD50 challenge doses per mouse.
  • the mice are killed by cervical dislocation, fixed with a 10% formaldehyde solution, routinely sampled, dehydrated, embedded in paraffin, stained with HE, and read under a light microscope.
  • the lesions are assigned as 0, 1, 2, 3 and 4 respectively.
  • Lesion scores are computed and statistical analysis is performed. A rank sum test is used, and statistical software SPSS13.0 is used.
  • Clinical efficacy criteria in 3 consecutive days of administration, body temperatures return to normal, symptoms of headache, limb soreness, dry throat, sore throat and cough are significantly relieved, and hemogram and chest X-rays are normal. Marked effect and relief are combined into effectivity, and the effective rate is up to 87%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.

Description

FIELD
The present disclosure relates to a Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof, and relates to the technical field of medicines.
BACKGROUND
Influenza (called the flu for short) is a respiratory tract infection mainly caused by influenza viruses, and is high in infectivity and spread rate. The typical clinical symptoms are fever, headache, limb soreness, sneezing, dry throat, sore throat, cough and weakness.
Until now, there has been no specific medicine for treating the influenza clinically, and the flu epidemic endangers social public health safety and health of people. As a result, research and development of a new medicine for viral influenza are in hot demand for modern society and national health.
SUMMARY
In order to solve the deficiencies of the prior art, the present disclosure provides a Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof.
Technical solution: For solving the above technical problem, the technical solutions used in the present disclosure are as follows:
In a first aspect, provided is a Fructus Forsythiae and Radix Astragali compound preparation, including traditional Chinese medicine formulation components. The traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae.
As a preferred solution, as for the Fructus Forsythiae and Radix Astragali compound preparation, the traditional Chinese medicine formulation components consist of the following components in parts by mass: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisiae Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae.
In some embodiments, the Fructus Forsythiae and Radix Astragali compound preparation includes an effective dose of the traditional Chinese medicine formulation components and a pharmaceutically acceptable excipient.
In some embodiments, dosage forms of the Fructus Forsythiae and Radix Astragali compound preparation include an oral liquid, a granule, a dissolved medicine, and a tablet.
In a second aspect, provided is a preparation method for a Fructus Forsythiae and Radix Astragali oral liquid, including
    • (1) preparing raw materials according to a formulation ratio: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisiae Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae; and washing the medicinal materials with water to remove impurities;
    • (2) soaking the medicinal materials in deionized water at 25° C. for 120 minutes;
    • (3) performing water extraction, and performing decocting at 100° C. for 20 minutes;
    • (4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
    • (5) performing potting and sterilizing to obtain a Fructus Forsythiae and Radix Astragali oral liquid.
In a third aspect, provided is a preparation method for a Fructus Forsythiae and Radix Astragali granule, including:
    • (1) preparing raw materials according to a formulation ratio: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisiae Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae; and washing the medicinal materials with water to remove impurities;
    • (2) soaking the medicinal materials in deionized water at 25° C. for 120 minutes;
    • (3) performing water extraction, and performing decocting at 100° C. for 20 minutes;
    • (4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
    • (5) performing drying, granulating, packaging and sterilizing to obtain a Fructus Forsythiae and Radix Astragali granule.
In a fourth aspect, provided is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.
In the formulation, monarch herbs include: Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, and Herba Artemisiae Annuae; minister herbs include: Radix Astragali, stir-fried Rhizoma Atractylodis Macrocephalae, and Herba Pogostemonis; assistant herbs include: Radix Saposhnikoviae and Radix Ophiopogonis; and an envoy herb is Radix Glycyrrhizae.
The formulation has functions of clearing heat and removing toxic substances, inhibiting virus activity, nourishing yin and relieving cough, benefiting lung and tonifying spleen, strengthening body resistance and eliminating pestilence. The formulation is applicable to influenza, fever, headache, limb soreness, sore throat, cough and asthenia.
Compared with existing traditional Chinese medicines, such as Zhengchaihuyin granule, Banlangen granule, Lianhua Qingwen capsule and Shuanghuanglian oral liquid, beneficial effects of the Fructus Forsythiae and Radix Astragali compound preparation, and the preparation method therefor and the use therefor provided in the present invention are: firstly, pharmaceutical components of the formulation are different from those of the existing related traditional Chinese medicines, and the pharmaceutical composition of the formulation is unique and novel. Secondly, an innovative point of efficacy of the drugs of the formulation lies in that by means of the pharmaceutical composition of the formulation, a strong medicine combined antiviral effect may be generated, and the immune function of the human body is further improved, so as to achieve a desirable integrated synergistic antiviral effect. For example, Flos Lonicerae, Fructus Forsythiae, and Radix Scutellariae all have antiviral effects, and the three traditional Chinese medicines are used in combination in the formulation to enhance the medicine antiviral effect. Moreover, Radix Scutellariae and Radix Glycyrrhizae in the formulation play a better integrated and synergistic antiviral effect by regulating the immune function of the human body, effectively inhibit virus activity, relieve symptoms of a patient, and achieve efficacy of strengthening body resistance and eliminating pathogens. Thirdly, a dialectical theory of the formulation on influenza treatment is unique and innovative, the innovative point is to propose “nourishing yin and relieving cough, benefiting lung and tonifying spleen, strengthening body resistance and eliminating pestilence” based on traditional heat clearing and toxic substance removing. For example, Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, and Herba Artemisiae Annuae enter lungs, a stomach, a liver, a gallbladder and a large intestine meridian, and have effects of clearing heat and removing toxic substances, clearing lung heat and relieving cough; Radix Astragali, stir-fried Rhizoma Atractylodis Macrocephalae and Herba Pogostemonis have effects of benefiting qi and reinforcing spleen, and enhance resistance of the human body; compatibility of Radix Saposhnikoviae with Radix Astragali and Rhizoma Atractylodis Macrocephalae is Yupingfeng San, and achieves functions of tonifying qi, consolidating superficial resistance, enhancing the immune function of the human body, and strengthening the body resistance. Herba Artemisiae Annuae reduces fever, Herba Pogostemonis eliminates dampness with aromatics, and clears lung-heat and relieves coughing. Radix Ophiopogonis nourishes yin and promotes production of body fluid, nourishes the lung to arrest coughing. Radix Glycyrrhizae invigorates spleen and replenishes qi, clears heat and removes toxic substances, and regulates various drugs to exert a synergistic effect.
DETAILED DESCRIPTION
The present disclosure will be specifically described hereafter in conjunction with embodiments.
Embodiment 1: Preparation of a Fructus Forsythiae and Radix Astragali Oral Liquid
Raw materials of a formulation are as follows: 100 parts of Flos Lonicerae, 100 parts of Fructus Forsythiae, 100 parts of Radix Scutellariae, 100 parts of Herba Artemisiae Annuae, 100 parts of Radix Astragali, 100 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 100 parts of Herba Pogostemonis, 60 parts of Radix Saposhnikoviae, 100 parts of Radix Ophiopogonis, and 60 parts of Radix Glycyrrhizae.
Preparation method and steps:
    • (1) washing medicinal materials with water to remove impurities;
    • (2) preparing the medicinal materials into 1000 parts by volume and soaking same in deionized water at 25° C. for 120 minutes;
    • (3) performing water extraction, and performing decocting at 100° C. for 20 minutes;
    • (4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
    • (5) potting and sterilizing to obtain a Fructus Forsythiae and Radix Astragali oral liquid.
Embodiment 2: Preparation of a Fructus Forsythiae and Radix Astragali Granule
Raw materials of a formulation are as follows: 100 parts of Flos Lonicerae, 100 parts of Fructus Forsythiae, 100 parts of Radix Scutellariae, 100 parts of Herba Artemisiae Annuae, 100 parts of Radix Astragali, 100 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 100 parts of Herba Pogostemonis, 60 parts of Radix Saposhnikoviae, 100 parts of Radix Ophiopogonis, and 60 parts of Radix Glycyrrhizae.
Preparation method and steps:
    • (1) washing medicinal materials with water to remove impurities;
    • (2) preparing the medicinal materials into 1000 parts by volume and soaking same in deionized water at 25° C. for 120 minutes;
    • (3) performing water extraction, and performing decocting at 100° C. for 20 minutes;
    • (4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
    • (5) drying, granulating, packaging and sterilizing to obtain a Fructus Forsythiae and Radix Astragali granule.
Embodiment 3: Influence of Fructus Forsythiae and Radix Astragali Granule on Lung Lesion in Mice Infected with Influenza Virus
Materials: a stock solution (15.6 g crude drug/kg) prepared from Fructus Forsythiae and Radix Astragali granules; ribavirin (positive control, 0.075 g/kg); and chicken embryo, influenza a virus FM1 strain, and ICR mice.
Method: the mice are randomly divided into four groups, each group has six mice, and a normal group, a model group, a ribavirin group, and a Fructus Forsythiae and Radix Astragali granule group are set. The mice are intragastrically administered twice a day, 0.3 ml each time, and the mice in the normal group are administered with double-distilled water at the same dose for five consecutive days. The mice are infected intranasally with virus allantoic droplets, at 15 LD50 challenge doses per mouse. On the sixth day, the mice are killed by cervical dislocation, fixed with a 10% formaldehyde solution, routinely sampled, dehydrated, embedded in paraffin, stained with HE, and read under a light microscope. Depending on different degrees of mild, moderate and severe lesions, the lesions are assigned as 0, 1, 2, 3 and 4 respectively. Lesion scores are computed and statistical analysis is performed. A rank sum test is used, and statistical software SPSS13.0 is used.
Results:
Table Influence of Fructus Forsythiae and Radix Astragali granule on degree of lung lesion in mice infected with influenza virus (n=6)
Lesion score
Hemorrhage and
congestion of lung Suppurative Interstitial
Group tissue bronchitis Bronchitis Alveolitis pneumonia
Normal group 0 0 0 0 0
Model group 12 18 15 13 8
Ribavirin group 7 9 3 3 2
Fructus Forsythiae 3 9 5 6 7
and Radix Astragali
granule group
Note:
(1) In different tissue lesions, differences between the model group, the ribavirin group and the Fructus Forsythiae and Radix Astragali granule group and the normal group have statistical significance (P < 0.05).
(2) Differences between the ribavirin group and the Fructus Forsythiae and Radix Astragali granule group have no statistical significance (P > 0.05).
The results show that the Fructus Forsythiae and Radix Astragali granule has an effect of reducing the lung lesions of the mice caused by influenza viruses.
Embodiment 4
In general data, from September 2019 to February 2020, patients with clinical influenza who complied with the following symptoms (fever, headache, limb soreness, dry throat, sore throat, cough) are enrolled in the study for oral administration of Fructus Forsythiae and Radix Astragali granule dissolved medicines. Thirty patients, aged 19-60 years, receive one dose of traditional Chinese medicine per day, twice in the morning and evening, for 3-5 consecutive days. Thirty control groups receive open parallel and conventional treatment for control.
Clinical efficacy criteria: in 3 consecutive days of administration, body temperatures return to normal, symptoms of headache, limb soreness, dry throat, sore throat and cough are significantly relieved, and hemogram and chest X-rays are normal. Marked effect and relief are combined into effectivity, and the effective rate is up to 87%.
The present disclosure is recited above in terms of preferred embodiments which are not intended to limit the present disclosure, and all technical solutions obtained by means of equivalent substitution or equivalent transformation fall within the scope of protection of the present disclosure.

Claims (7)

What is claimed is:
1. A Fructus Forsythiae and Radix Astragali compound preparation wherein the active agents consist of the following raw material extracts in parts by mass: 9-11 parts of an aqueous extract of Flos Lonicerae, 9-11 parts of an aqueous extract of Fructus Forsythiae, 9-11 parts of an aqueous extract of Radix Scutellariae, 9-11 parts of an aqueous extract of Herba Artemisiae Annuae, 9-11 parts of an aqueous extract of Radix Astragali, 9-11 parts of an aqueous extract of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of an aqueous extract of Herba Pogostemonis, 5-7 parts of an aqueous extract of Radix Saposhnikoviae, 9-11 parts of an aqueous extract of Radix Ophiopogonis, and 5-7 parts of an aqueous extract of Radix Glycyrrhizae.
2. The Fructus Forsythiae and Radix Astragali compound preparation according to claim 1, wherein,
the compound preparation consists of the following components in parts by mass: 10 parts of an aqueous extract of Flos Lonicerae, 10 parts of an aqueous extract of Fructus Forsythiae, 10 parts of an aqueous extract of Radix Scutellariae, 10 parts of an aqueous extract of Herba Artemisiae Annuae, 10 parts of an aqueous extract of Radix Astragali, 10 parts of an aqueous extract of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of an aqueous extract of Herba Pogostemonis, 6 parts of an aqueous extract of Radix Saposhnikoviae, 10 parts of an aqueous extract of Radix Ophiopogonis, and 6 parts of an aqueous extract of Radix Glycyrrhizae.
3. The Fructus Forsythiae and Radix Astragali compound preparation according to claim 1, wherein,
dosage forms of the Fructus Forsythiae and Radix Astragali compound preparation comprise an oral liquid, a granule, a dissolved medicine, and a tablet.
4. A preparation method for a Fructus Forsythiae and Radix Astragali oral liquid, comprising the following steps:
(1) preparing raw materials according to a formulation ratio: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisia Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae; and washing the medicinal materials with water to remove impurities;
(2) soaking the medicinal materials in deionized water at 25° C. for 120 minutes;
(3) performing water extraction, and performing decocting at 100° ° C. for 20 minutes;
(4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
(5) performing potting and sterilizing to obtain a Fructus Forsythiae and Radix Astragali oral liquid.
5. A preparation method for a Fructus Forsythiae and Radix Astragali granule, comprising the following steps:
(1) preparing raw materials according to a formulation ratio: 10 parts of Flos Lonicerae, 10 parts of Fructus Forsythiae, 10 parts of Radix Scutellariae, 10 parts of Herba Artemisiae Annuae, 10 parts of Radix Astragali, 10 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 10 parts of Herba Pogostemonis, 6 parts of Radix Saposhnikoviae, 10 parts of Radix Ophiopogonis, and 6 parts of Radix Glycyrrhizae; and washing the medicinal materials with water to remove impurities;
(2) soaking the medicinal materials in deionized water at 25° ° C. for 120 minutes;
(3) performing water extraction, and performing decocting at 100° C. for 20 minutes;
(4) leaving a decoction to stand at 4° C. for 12 hours, filtering and concentrating the decoction, and adding benzoic acid or sodium benzoate; and
(5) performing drying, granulating, packaging, and sterilizing to obtain a Fructus Forsythiae and Radix Astragali granule.
6. The Fructus Forsythiae and Radix Astragali compound preparation according to claim 2, comprising an effective dose of the traditional Chinese medicine formulation components and a pharmaceutically acceptable excipient.
7. The Fructus Forsythiae and Radix Astragali compound preparation according to claim 6, wherein,
dosage forms of the Fructus Forsythiae and Radix Astragali compound preparation comprise an oral liquid, a granule, a dissolved medicine, and a tablet.
US17/788,010 2020-03-12 2020-07-14 Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof Active 2040-07-14 US11998583B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010168799.0 2020-03-12
CN202010168799.0A CN111249390B (en) 2020-03-12 2020-03-12 A compound preparation of Qiqi and its preparation method and use
PCT/CN2020/101945 WO2021179505A1 (en) 2020-03-12 2020-07-14 Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof

Publications (2)

Publication Number Publication Date
US20230040479A1 US20230040479A1 (en) 2023-02-09
US11998583B2 true US11998583B2 (en) 2024-06-04

Family

ID=70945818

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/788,010 Active 2040-07-14 US11998583B2 (en) 2020-03-12 2020-07-14 Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof

Country Status (6)

Country Link
US (1) US11998583B2 (en)
EP (1) EP4066848B1 (en)
JP (1) JP7560154B2 (en)
KR (1) KR20220098360A (en)
CN (1) CN111249390B (en)
WO (1) WO2021179505A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249390B (en) * 2020-03-12 2025-07-04 尧舜泽生物医药(南京)有限公司 A compound preparation of Qiqi and its preparation method and use
CN113577140A (en) * 2021-07-28 2021-11-02 黑龙江中医药大学附属第一医院（黑龙江中医药大学第一临床医学院） Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof
CN113925835A (en) * 2021-09-29 2022-01-14 孙鲁英 Exterior-strengthening lung-clearing granules and preparation method thereof
CN114606236B (en) * 2022-04-21 2024-01-05 南通大学 Micro ribonucleic acid from Chinese medicinal decoction of radix astragali, and preparation method and application thereof
CN118384239A (en) * 2022-12-12 2024-07-26 北京揆正中医药科技有限公司 A composition for strengthening the body and preventing and treating COVID-19 and a preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740370A (en) * 2013-12-26 2015-07-01 孔辉 Drug for preventing and treating avian influenza

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101816752B (en) * 2009-02-26 2011-08-31 河南天纳图生物科技有限公司 Traditional Chinese medicament for preventing and treating avian influenza
CN101574407B (en) * 2009-06-24 2011-04-13 贾高增 Drug for preventing cold and preparation method thereof
CN101708275B (en) * 2009-11-27 2012-11-28 北京市卫生局临床药学研究所 Chinese medicament for treating flu caused by influenza A(H1N1) and the like
CN104013678B (en) * 2014-05-24 2016-02-17 潍坊市富言畜禽病诊疗中心 A kind of Chinese medicine composition for preventing and treating bird flu, newcastle
CN104840786B (en) * 2015-05-14 2019-02-15 北京康华远景科技股份有限公司 A kind of pharmaceutical composition and preparation method thereof of pre- avian influenza-prevention
CN109939152A (en) * 2017-12-20 2019-06-28 广东恒诚制药有限公司 A kind of preparation method and application for cough-stopping granule of catching a cold
CN111249390B (en) * 2020-03-12 2025-07-04 尧舜泽生物医药(南京)有限公司 A compound preparation of Qiqi and its preparation method and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740370A (en) * 2013-12-26 2015-07-01 孔辉 Drug for preventing and treating avian influenza

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gu, S., et al., Antitumor, Antiviral, and Anti-Inflammatory Efficacy of Essential Oils from Atractylodes macrocephala Koidz. Produced with Different Processing Methods, Molecules 2019, 24(16), 2956 (Year: 2019). *
Gu, S., et al., Understanding molecular mechanisms of traditional Chinese medicine for the treatment of influenza viruses infection by computational approaches, Mol. Bio Syst., 2013, 9, 2696 (Year: 2013). *
Machine translation of CN-104740370-A Description (2023). *
Machine translation of CN-104740370-A Description. *

Also Published As

Publication number Publication date
JP2023508675A (en) 2023-03-03
EP4066848A4 (en) 2023-01-04
JP7560154B2 (en) 2024-10-02
EP4066848A1 (en) 2022-10-05
EP4066848B1 (en) 2025-11-26
CN111249390B (en) 2025-07-04
CN111249390A (en) 2020-06-09
WO2021179505A1 (en) 2021-09-16
US20230040479A1 (en) 2023-02-09
KR20220098360A (en) 2022-07-12

Similar Documents

Publication Publication Date Title
US11998583B2 (en) Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof
CN111265616B (en) Traditional Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia
CN111317798A (en) Traditional Chinese medicine composition for detoxifying, eliminating dampness and relieving sore throat and application thereof
WO2021208336A1 (en) Traditional chinese medicine composition and use thereof
CN111110819A (en) Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza
CN1437963A (en) Medicine for treating cold and preparation method thereof
CN102657804B (en) Traditional Chinese medical composition for treatment of viral influenza and preparation method thereof
AU2021106785C4 (en) Combined plant compounds for use in the treatment of viral infections including covid-19
CN118161584B (en) Traditional Chinese medicine composition for treating fever cough and expectoration
CN104958419B (en) The careless capsule for clearing away heat of gold and manufacture craft
CN113350429B (en) Traditional Chinese medicine composition for preventing and treating African swine fever disease as well as preparation method and application thereof
CN111544466B (en) Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing neocoronary pneumonia
EA044883B1 (en) MULTICOMPONENT DRUG, METHOD OF PREPARING ENCAPSULATED LIQUID FOR ORAL ADMINISTRATION OF THIS DRUG, METHOD OF PREPARING ENCAPSULATED GRANULES OF THIS DRUG AND APPLICATION
CN118717901A (en) A Chinese medicine composition and a drug preparation for dispelling exterior pathogens and clearing interior pathogens
CN117503882A (en) Traditional Chinese medicine compositions and their preparations and uses
CN111228432A (en) Traditional Chinese medicine composition for treating viral influenza and preparation and application thereof
HK40024248B (en) Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia
HK40024248A (en) Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia
UPADHYAY HERBAL TREATMENTS FOR RESPIRATORY VIRAL DISEASES
CN120771237A (en) Traditional Chinese medicine composition for treating qi deficiency cold and preparation and application thereof
CN118490778A (en) A Chinese medicine composition for treating African swine fever and its application
CN113842446A (en) Traditional Chinese medicine composition for preventing and treating influenza
CN118576666A (en) A compound antiviral Chinese medicine preparation and its preparation method
CN105412407A (en) Traditional Chinese medicine composition for preventing and curing flu as well as preparation method and application thereof
CN120550026A (en) A Chinese medicine composition and its application

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

AS Assignment

Owner name: NANTONG UNIVERSITY, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GU, XIAOSONG;TANG, CHUNKANG;GONG, LEILEI;AND OTHERS;REEL/FRAME:067129/0430

Effective date: 20220606

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE